How much funding has Georgiamune raised?

Georgiamune has raised $75.0M in total funding, most recently a Series A round.

Who are Georgiamune's investors?

Georgiamune's investors include General Catalyst, Parker Institute for Cancer Immunotherapy, Mubadala Capital, Alexandria Venture Investments, Catalio Capital Management, CJNV BioVentures.

When was Georgiamune founded?

Georgiamune was founded in 2023.

Where is Georgiamune headquartered?

Georgiamune is headquartered in Gaithersburg, Maryland, United States.

What industry is Georgiamune in?

Georgiamune operates in Life Sciences, Biotech, Therapeutics, Healthcare.

How many employees does Georgiamune have?

Georgiamune has 11-50 employees.

Georgiamune

Reprogramming immune responses.

Gaithersburg, United States · Founded 2023 · $75.0M raised

Headquarters: Gaithersburg, Maryland
Employees: 11–50
Founded: 2023
Business Model: B2B

Website: georgiamune.com
Total Funding: $75.0M
Last Round: $75.0M Series AAug 2023
Rounds: 1

About

Georgiamune is a clinical-stage biotechnology company focused on transforming immunotherapy by reprogramming immune signaling pathways to restore immune homeostasis. Founded by Dr. Samir N. Khleif, the company has built a first-in-class target discovery platform that has generated a robust pipeline of immunomodulators — including dual-functioning antibodies and small molecule Treg inhibitors and activators — targeting cancer and autoimmune diseases. Georgiamune has advanced multiple assets into Phase 1 clinical trials, including GIM-531, GIM-407, and GIM-122, and continues to expand its pipeline with novel biologics and small molecules addressing large indications with high unmet need.

Summary

Georgiamune is a Life Sciences company based in Gaithersburg, United States, founded in 2023. It has raised $75.0M in total across 1 round, most recently a $75.0M Series A round in Aug 2023. Investors include General Catalyst, Parker Institute for Cancer Immunotherapy and Mubadala Capital.